Foodie Pundit

The FDA Gets a Scolding on Food Safety From a Watchdog

The federal government's own watchdog says the FDA isn't doing enough to make sure the ingredients in your food are actually safe.

By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

Food service activity related to this story. Representative image.

Key points

  • A federal watchdog says the FDA's system for ensuring new food ingredients are safe has serious weaknesses.
  • The "Generally Recognized as Safe" (GRAS) rule lets companies decide for themselves if an ingredient is safe, without mandatory FDA approval.
  • The Government Accountability Office (GAO) found the FDA rarely challenges companies' safety claims and lacks a systematic way to review ingredients already on the market.
  • The GAO recommends that the FDA require companies to submit all GRAS determinations and that the agency should periodically review previously cleared ingredients.

The public's trust in the American food supply rests on the assumption of rigorous government oversight. A new intelligence report from within the federal government challenges that assumption, concluding that the U.S. Food and Drug Administration's system for policing new food ingredients contains procedural flaws that benefit industry at the expense of comprehensive safety review.

The official record shows that the agency tasked with safeguarding 80 percent of the nation's food permits a system where companies can, and do, introduce novel substances into foods with no mandatory government safety check. This is not an accusation from an outside critic. It is the formal conclusion of the U.S. Government Accountability Office, an independent, non-partisan federal agency that serves as the investigative arm of Congress. The Official Finding

In an August 2026 report, the Government Accountability Office, or GAO, delivered a direct message to the Food and Drug Administration. The report, titled "FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be GRAS," documents significant deficiencies in the regulatory framework for substances that are "Generally Recognized as Safe." The GAO's function is to audit federal programs, and its reports represent official findings of procedural or structural failures. The use of "Should" in a GAO report title is a direct and public recommendation for corrective action by the audited agency.

The report lays out how the FDA's current approach to GRAS ingredients hampers the agency's ability to fulfill its public health mission. The core of the finding is that the system is voluntary. Companies that introduce new ingredients are not required to inform the FDA, which prevents the agency from having a complete understanding of what substances are in the food supply and what potential risks they might pose.

This is not a dispute over administrative paperwork. It is a story documented in federal records about who decides what is safe to eat, who benefits from the current system, and where the authority for public safety actually resides.

The authority over the safety of the American food supply is held by the FDA, specifically its Center for Food Safety and Applied Nutrition, or CFSAN. This authority is granted by the Federal Food, Drug, and Cosmetic Act. Under that foundational public health law, any substance intentionally added to food is classified as a "food additive."

As a food additive, it is subject to mandatory and rigorous premarket approval by the FDA. A manufacturer must submit a formal petition with extensive safety data, a process that can take years and require millions of dollars in scientific studies.

The law, however, contains a critical exception first written in 1958. It exempts substances that are "generally recognized, among qualified experts, as having been adequately shown through scientific procedures... to be safe under the conditions of its intended use."

This is the GRAS exception. The GAO report documents that what was intended as a carve-out for common substances like vinegar and salt has become a primary pathway for novel, manufactured ingredients.

Under this system, the decider changes. Instead of the FDA, the food or ingredient manufacturer itself becomes the initial arbiter of safety. A company can convene its own panel of experts to review scientific evidence and make a GRAS determination.

The GAO report confirms that the company is not legally required to inform the FDA that it has made this determination and begun using the ingredient in products. These are known as "independent conclusions." The FDA, the agency with statutory authority, is left without knowledge or oversight of these decisions.

When a company does choose to inform the FDA, it submits a voluntary GRAS notification. The FDA's review of this notification does not result in an "approval." Instead, the agency may issue a "no questions" letter.

This letter states that the agency has reviewed the company's submission and does not disagree with its conclusion at this time. This legal distinction means the safety responsibility remains with the company, and the FDA has only passively reviewed the company's own conclusion. The GAO report identifies this reactive posture as a core weakness. Who Benefits From The Gaps

The primary beneficiaries of the GRAS system, as described in the GAO audit, are food and ingredient manufacturers. The report details a system that provides substantial financial and competitive advantages to these companies.

The chief benefit is bypassing the formal food additive petition process. That process is lengthy, expensive, and its outcome is uncertain. By using the GRAS pathway, particularly the "independent conclusion" route where the FDA is not notified, a company can bring a new ingredient to market in a fraction of the time and at a fraction of the cost. This speed to market provides a significant competitive advantage, allowing a company to launch new products or reformulate existing ones far ahead of competitors who may be using the more cumbersome formal review process.

The system also benefits companies by allowing them to maintain control over proprietary information. The GRAS process, especially when conducted internally without a notification to the FDA, can shield the company's research and even the identity of the novel ingredient from public and competitor scrutiny.

The GAO report makes it clear that these companies are not necessarily acting outside the law. They are responding to the incentives built into the regulatory framework. The path of least resistance is the GRAS determination, a regulatory fast lane that prioritizes innovation and speed over mandatory federal premarket review. The gain is measured in market share and revenue secured months or years before a formal FDA approval process could be completed. The Regulated Party Decides

The central conflict identified in the federal record is the overlap between the beneficiary and the decider. The GRAS system allows the regulated entity, the food manufacturer, to perform the role of the regulator.

The GAO report describes a process where a company seeking to profit from a new ingredient is the same entity that initiates and manages the safety assessment. The company can select the scientific evidence to be reviewed. It can select the "qualified experts" who will perform the review.

If this hand-picked panel agrees with the company's desired conclusion, the ingredient is deemed GRAS. This entire process can occur without the FDA's knowledge.

This is the point of overlap: the body that gains a financial benefit from a positive safety determination is the same body that controls the process of making that determination. The GAO report concludes that this structure creates an inherent conflict of interest. The system is designed in a way that the FDA, the ostensible public safety agency, is not a gatekeeper but a passive observer that may or may not be informed after the fact. While the FDA retains the authority to challenge an ingredient's GRAS status if it later finds evidence of a safety problem, its ability to do so proactively is, according to the GAO, severely limited by the information asymmetry the current system creates. A Timeline of Regulatory Delegation

The sequence of events documented in public records reveals how a narrow legal exception evolved into a primary regulatory pathway. The timeline demonstrates a progressive delegation of safety assessment from the federal government to private industry.

First, in 1958, the U.S. Congress passed the Food Additives Amendment to the Federal Food, Drug, and Cosmetic Act. This law established mandatory premarket approval for food additives but created the GRAS exception for substances widely understood to be safe.

Second, in the following decades, food science and manufacturing technology advanced rapidly. Industry practice began to apply the 1958 exception to novel, highly engineered ingredients, not just common kitchen staples. This interpretation expanded the scope of the GRAS pathway far beyond its original intent.

Third, the current system of "independent conclusions" became common practice. As documented in the GAO's 2026 report, companies now routinely complete their own GRAS determinations for new ingredients without any requirement to notify the FDA. This represents the peak of the delegation, where the federal regulator has no visibility into the entry of a new substance into the food supply.

Fourth, the practice of voluntary GRAS notifications and the FDA's "no questions" letter response became codified. This created a formal, but optional, channel for communication that legally maintains the company's responsibility for the safety determination, with the FDA taking no approval role.

Finally, on August 11, 2026, the Government Accountability Office published its report, "FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be GRAS." This document serves as an official capstone to this timeline, a federal audit concluding that the cumulative effect of these practices has resulted in a regulatory system with significant deficiencies that fails to provide the FDA with the information it needs to fully protect public health. The report formally recommends that the FDA take specific actions to correct these deficiencies. What The Record Proves And What It Does Not

It is critical to distinguish what this federal paper trail establishes from what it does not. The Government Accountability Office report is an activity record, not a criminal indictment or a finding of specific harm. Its purpose is to audit process, authority, and execution.

The record proves the following: The FDA's regulatory framework for new food ingredients contains a significant loophole. This loophole allows a company to determine for itself that an ingredient is safe, with no mandatory requirement to inform the FDA. The GAO, an official government body, has concluded this system is a deficiency that hampers the FDA's ability to protect public health. The report establishes that an inherent conflict of interest exists when a company with a financial stake in an ingredient's use is also responsible for affirming its safety.

The record does not prove that any specific ingredient determined to be GRAS through an independent conclusion is, in fact, unsafe. The GAO report is a systemic critique; it does not analyze the safety of individual substances. It does not prove that any company has acted illegally.

A company making an independent GRAS conclusion is operating within the letter of the current, flawed regulations. The report is a finding that the regulations themselves are inadequate, not a list of companies that have broken the law. An activity record documents what happened; it is not, by itself, proof of wrongdoing.

The GAO's findings are about systemic risk, not adjudicated harm. Systemic Risk and Lack of Transparency

The most immediate consequence of the system described by the GAO is a lack of transparency that introduces systemic risk. Because notification is voluntary, no complete and public list of all ingredients currently being used in foods under a GRAS determination exists. According to the GAO's findings, an ingredient can be present in foods for years without the FDA knowing of its existence, much less having reviewed its safety data.

This information deficit has tangible consequences for public health oversight. The GAO report notes that without a full picture of the substances entering the food supply, the FDA cannot effectively monitor for potential health risks. The agency is unable to assess the cumulative effect of multiple, similar ingredients from different sources.

For individuals with food sensitivities or allergies, the introduction of novel, unreviewed proteins and chemical compounds presents unquantified risks. The GAO's concern about "potential health risks" is the formal language of a risk assessment agency flagging a procedural failure that could lead to negative health outcomes.

The erosion of trust is a significant, if less tangible, consequence. The social contract of food regulation is that the public delegates the complex work of toxicology and chemistry to impartial experts at the FDA. The GAO report documents that for a significant portion of ingredients, this delegation has been intercepted and redirected to corporate experts whose employers have a vested financial interest in a positive safety outcome. What to watch next

The publication of the GAO report is a starting point, not an end. It initiates a public process of accountability. The following concrete milestones will determine whether the findings lead to substantive change.

First, the FDA's formal response to the report is the immediate next step. Federal agencies are typically required to provide a written response to GAO recommendations within 60 days. In this response, the FDA will state whether it "concurs" or "non-concurs" with the findings and outline its planned actions.

This response will be made public and will be the first official signal of the agency's intentions. A full concurrence with a detailed action plan would indicate a commitment to reform.

Second, any meaningful change, such as making GRAS notifications mandatory, would likely require a formal rulemaking process. The initiation of this process begins with a publication in the Federal Register, which opens a public comment period. This allows industry, scientists, advocacy groups, and citizens to submit evidence and opinions. The start of such a process is a serious, though lengthy, step toward addressing the GAO's findings.

More from the Foodie Pundit Newsroom

Permalink